Evaluation of an antioxidant and mitochondrial stimulating cream formula in the skin of patients with stable vulgar vitiligo;Evaluación de una formulación antioxidante y estimuladora mitocondrial en piel de pacientes con vitiligo vulgar estable

Investigacion Clinica

Volumn 48, Issue 1, 2007, Pages 21-31

  Rojas Urdaneta, Janeth Elizabeth ^a,b   Poleo Romero, Abel Gustavo ^a  

^a UNIVERSIDAD DE CARABOBO   (Venezuela)

^b Núcleo Aragua   (Venezuela)

Author keywords

Anti oxidant; Antioxidant mitochondrial; Antivitiligo treatment; Melanocyte; Oxidative stress; Vitiligo

Indexed keywords

ANTIOXIDANT; FREE RADICAL; PHENYLALANINE; PLACEBO; PYRIDOXINE; UBIDECARENONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CYTOTOXICITY; DOUBLE BLIND PROCEDURE; DRUG FORMULARY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MITOCHONDRION; RANDOMIZED CONTROLLED TRIAL; STABLE VULGAR VITILIGO; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIOXIDANTS; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MELANOCYTES; MINERALS; MITOCHONDRIA; OINTMENTS; OXIDATIVE STRESS; PHENYLALANINE; PLANT PREPARATIONS; SKIN; SKIN PIGMENTATION; VITAMINS; VITILIGO;

EID: 34248178939     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Margasin SM. Vitiligo. Piet 2000; 15:436-441.
2. Seung-Kyung H. Vitiligo. Medicine Journal 2001; 2(1):1-10.
3. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol. Sci. 2005; 39(3):137-146.
4. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38:647-666.
5. Nordlund JJ, Majunder PP. Investigaciones recientes sobre vitiligo vulgar. Clínicas dermatológicas 1997; 1:71-80.
6. Buxton PK. ABC de la dermatología. México: BMJ Latino américa, 1998. p. 105.
7. Boisseau-Gargaud AM, Vezon G, Helenon R, Garsaud P, Saint-Cyr I, Quist D. High prevalence of vitiligo in lepromatous leprosy. Int Dermatol. 2000; 39:837-839.
8. Sánchez CI, España AA. Role the Neuropeptides in dermatology. Rev Neurol 1997; 25(3):221-231
9. Davis MD, Ribeiro P,Tipper J, Kaufman S. '7-Tetrahydrobiopterin, a naturally occurring analogue of tetrahydrobiopterin, is a cofactor for and a potential inhibitor of the aromatic amino acid hydroxylases. Poc Natl. Acad Sci USA 1992; 89:10108-10113.
10. Schallreuter KU, Wood JM, Pittelkow MR. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996; 288(1): 14-18.
11. Stark JM. Immunological adjunvance of metabolic origin: oxidative stress, postulated impaired function of thiol proteases and immunogenicity. Scand J Immunol 1998; 48:475-479.
12. Freeman BA, Crapo JD. Free radicals and tissue injury. Lab Invest 1982; 47:412-415.
13. Basaga HS. Biochemical aspects of free radicals. Biochem Cell Biol 1989; 68:989-998.
14. Gerschman R. Oxigen poisoning and X-Irradiation. A mechanism in common. Science 1954; 119:623-626.
15. Hazneci E, Karabulut AB, Oztürk C, Batcioglu K, Dogan G, Karaca A, Esrefoglu M. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol. 2005;44(8):636-640.
16. Jeong YM, Choi YG, Kim DS, Park SH, Yoon JA, Kwon SB, Park ES, Park KC. Cytoprotective effect of green tea extract and quercetin against hydrogen peroxide-induced oxidative stress. Arch Pharm Res. 2005; 28(11):1251-1256.
17. Packer L. Vitamin E is nature's master antioxidant. Sci Am Sci Med 1994; 1:54-63.
18. Kuiters GRR, Middelkamp Hup J, Siddiqui AH, Cormane RH. Oral phenylalanine loading and sunlight as source of UVA irradiation in vitiligo on the Caribbean island of Curacao NA. J Trop Med Hyg 1986; 89:149-155.
19. Camacho F. L-Fenilalani na en el tratamiento del vitiligo. Monogr Dermatol 1995; 8:190-204.
20. Cormane RH, Siddiqui AH, Westerhof W, Schutgens RBH. Phenylalanine and UVA light for the tratament of vitiligo. Arch Dermatol Res 1985; 277:126-130.
21. Antoniou C, Schulpis H, Michas T, Katsambas A, Frajis N, Tsagaraki S. Stratigos J. Vitiligo therapy with oral and tropical phenylalanine. Science 1989;28(8):545-547.
22. Rayan WI, Carver MJ. Inhibition of antibody synthesis by L-Phenylalanine. Science 1964; 143:479-480.
23. Ryan WI. Inhibition of immune response by phenylalanine. JAMA 1965; 191:119-120.
24. Westerhof W, Groot I, Krieg SR, Bos JD, Cormane RH. Langerhans'cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venereol (Stockh) 1986; 66:259-262.
25. Biella U, Haustein UF. Behandlung der vitiligo mit phenylalanine und UVA-bestrahlung. Hautarzt 1990; 41:636.
26. Turrens J. Fuentes intracelulares de especies oxidantes en condiciones normales y patológicas. Antioxidante y Calidad de Vida. 1994; 1:16-19.
27. Tosaki A, Droy-Lefaix MI, Pali L, Das DK. Effects of SOD, catalase and a novel antiarrhymic drug. EGB 761 on perfusion induced arrhythmias in isolated rat hearts. Free Radic Biol Med 1993; 14:361-370.
28. Stepanik TM, Edwing DD. Coisolation of glutathione peroxidase, catalase and superoxide dismutase from human erythrocytes. J Biochem Biophys Methods 1990; 20(2):157-169.
29. Mosher DB, Fitzpatrick TB, Ortone JP. Desórdenes de los melanocitos. En: Fitz patrick E, Wolf FA. Dermalogía en medicina general. 2a ed. Buenos Aires: Médica Panamericana 1997. pp. 626-682.
30. Lee AY, Jang JH. Autologous epidermal grafting with PUVA irradiated donor skin for the treatment of vitiligo. Int J Dermatol 1998; 37:551-554.
31. Kumagai N, Uchikoshi T. Treatment of extensive hypomelanosis with autologous cultured epithelium. Ann Plast Surg 1997; 39:68-73
32. Woodley DT, O'keefe EJ, Pruneiras M. Cutaneous wound healing: A model for cell-matrix interactions. J Am Acad Dermatol 1985; 12:420-433.